14.77 USD
+2.08 (+16.39%)
12.91 USD
-1.86 (-12.59%)
Taking everything into account, NBY scores 3 out of 10 in our fundamental rating. NBY was compared to 191 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of NBY have multiple concerns. NBY is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- In the past year NBY has reported negative net income.
- In the past year NBY has reported a negative cash flow from operations.
- NBY had negative earnings in each of the past 5 years.
- NBY had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- NBY's Return On Assets of -251.48% is on the low side compared to the rest of the industry. NBY is outperformed by 90.05% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -251.48% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-178.5%
ROA(5y)-127.06%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- NBY's Gross Margin of 66.26% is fine compared to the rest of the industry. NBY outperforms 75.39% of its industry peers.
- In the last couple of years the Gross Margin of NBY has declined.
- The Profit Margin and Operating Margin are not available for NBY so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 66.26% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.12%
GM growth 5Y-2.09%
2. Health
2.1 Basic Checks
- NBY does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, NBY has more shares outstanding
- The number of shares outstanding for NBY has been increased compared to 5 years ago.
- Compared to 1 year ago, NBY has a worse debt to assets ratio.
2.2 Solvency
- NBY has an Altman-Z score of 237.10. This indicates that NBY is financially healthy and has little risk of bankruptcy at the moment.
- NBY's Altman-Z score of 237.10 is amongst the best of the industry. NBY outperforms 98.95% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | 237.1 |
ROIC/WACCN/A
WACC9.38%
2.3 Liquidity
- NBY has a Current Ratio of 0.68. This is a bad value and indicates that NBY is not financially healthy enough and could expect problems in meeting its short term obligations.
- NBY has a worse Current ratio (0.68) than 90.58% of its industry peers.
- NBY has a Quick Ratio of 0.68. This is a bad value and indicates that NBY is not financially healthy enough and could expect problems in meeting its short term obligations.
- NBY has a worse Quick ratio (0.41) than 90.58% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.68 | ||
| Quick Ratio | 0.41 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 84.82% over the past year.
- The Revenue for NBY has decreased by -33.58% in the past year. This is quite bad
- NBY shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 8.19% yearly.
EPS 1Y (TTM)84.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.24%
Revenue 1Y (TTM)-33.58%
Revenue growth 3Y5.12%
Revenue growth 5Y8.19%
Sales Q2Q%-38.05%
3.2 Future
- NBY is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 31.55% yearly.
- NBY is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 21.46% yearly.
EPS Next Y39.01%
EPS Next 2Y31.55%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year11.73%
Revenue Next 2Y21.46%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for NBY. In the last year negative earnings were reported.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NBY. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- NBY's earnings are expected to grow with 31.55% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.55%
EPS Next 3YN/A
5. Dividend
5.1 Amount
- With a Yearly Dividend Yield of 5.42%, NBY is a good candidate for dividend investing.
- NBY's Dividend Yield is rather good when compared to the industry average which is at 0.40. NBY pays more dividend than 97.91% of the companies in the same industry.
- Compared to an average S&P500 Dividend Yield of 1.85, NBY pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 5.42% |
5.2 History
- NBY does not have a reliable dividend history as it only pays dividend since a couple or years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y31.55%
EPS Next 3YN/A
14.77
+2.08 (+16.39%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-05 2025-11-05/amc
Earnings (Next)03-31 2026-03-31/amc
Inst Owners0.99%
Inst Owner Change0%
Ins Owners0%
Ins Owner Change0%
Market Cap1.86B
Revenue(TTM)9.78M
Net Income(TTM)-8.61M
Analysts80
Price Target0.87 (-94.11%)
Short Float %0.25%
Short Ratio0.29
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 5.42% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-17.67%
Min Revenue beat(2)-27.48%
Max Revenue beat(2)-7.85%
Revenue beat(4)0
Avg Revenue beat(4)-20.15%
Min Revenue beat(4)-27.48%
Max Revenue beat(4)-7.85%
Revenue beat(8)2
Avg Revenue beat(8)-7.51%
Revenue beat(12)4
Avg Revenue beat(12)-7.15%
Revenue beat(16)5
Avg Revenue beat(16)-5.76%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 190.28 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-7.41
EYN/A
EPS(NY)-0.87
Fwd EYN/A
FCF(TTM)-0.04
FCFYN/A
OCF(TTM)-0.04
OCFYN/A
SpS0.08
BVpS0
TBVpS0
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -251.48% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 66.26% | ||
| FCFM | N/A |
ROA(3y)-178.5%
ROA(5y)-127.06%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.12%
GM growth 5Y-2.09%
F-Score4
Asset Turnover2.86
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 15% | ||
| Cap/Sales | 0.06% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.68 | ||
| Quick Ratio | 0.41 | ||
| Altman-Z | 237.1 |
F-Score4
WACC9.38%
ROIC/WACCN/A
Cap/Depr(3y)15.76%
Cap/Depr(5y)29.79%
Cap/Sales(3y)0.32%
Cap/Sales(5y)0.37%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)84.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.24%
EPS Next Y39.01%
EPS Next 2Y31.55%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-33.58%
Revenue growth 3Y5.12%
Revenue growth 5Y8.19%
Sales Q2Q%-38.05%
Revenue Next Year11.73%
Revenue Next 2Y21.46%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y0.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year51.27%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-34.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-34.57%
OCF growth 3YN/A
OCF growth 5YN/A
NOVABAY PHARMACEUTICALS INC / NBY FAQ
Can you provide the ChartMill fundamental rating for NOVABAY PHARMACEUTICALS INC?
ChartMill assigns a fundamental rating of 3 / 10 to NBY.
Can you provide the valuation status for NOVABAY PHARMACEUTICALS INC?
ChartMill assigns a valuation rating of 1 / 10 to NOVABAY PHARMACEUTICALS INC (NBY). This can be considered as Overvalued.
Can you provide the profitability details for NOVABAY PHARMACEUTICALS INC?
NOVABAY PHARMACEUTICALS INC (NBY) has a profitability rating of 1 / 10.
What is the expected EPS growth for NOVABAY PHARMACEUTICALS INC (NBY) stock?
The Earnings per Share (EPS) of NOVABAY PHARMACEUTICALS INC (NBY) is expected to grow by 39.01% in the next year.